Recent Updates
Recently added Catalysts

Jazz Pharmaceuticals plc

JAZZFDA catalysts, PDUFA dates & pipeline intelligence
$240.71
▲ +0.94 · +0.39%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full JAZZ financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $156.9552W HIGH $266.38
Volume
499.52 K
Value Traded
120.04 M
Short % Float
9.4%
Days to Cover
7.7
-3.03%Week
+15.49%1 Month
-4.54%3 Month
+0.71%6 Month
+33.83%5 Year
+1,270.46%All Time

Cash Data

Unlock JAZZ cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
15.45 B
EPS (TTM)
3.21
P/E Ratio
75.02
Ent. Value
19.18 B
Total Shares
64.19 M
Float Shares
61.66 M
Insiders
3.94%
Institutions
104.45%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 3 data presentation
Ziihera (zanidatamab-hrii) plus Tevimbra (tislelizumab-jsgr) and chemotherapy
HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA)
PriorityFast TrackOrphan
Phase 3BiologicsOncology
Unlock every JAZZ catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

JAZZ Catalyst Timeline

Dated clinical, regulatory and corporate events for Jazz Pharmaceuticals plc

Catalyst Timeline

Dated clinical, regulatory & corporate events for Jazz Pharmaceuticals plc

1231Total events
18Upcoming
352Tier-1 (high impact)
2012 to 2030Coverage

Upcoming catalysts 2

T1Acquisition
Subscribe to view catalyst details
T2Oral Presentation
Subscribe to view catalyst details
ZanidatamabApproved

Event history 50

▲Quarterly UpdateCorporate
Reported third quarter 2026 financial results with record revenues of $1.2 billion
▲Runway Guidance UpdateCorporate
Raised 2026 total revenue guidance to $4.775-$4.85 billion
▲Late-BreakerZanidatamabApprovedPresentation
HERIZON-GEA-01 results presented as late-breaking oral at ESMO 2026
HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA)source ↗
▲Full ResultsZanidatamabApprovedClinical Data
Three-year OS results from HERIZON-GEA-01 presented at ESMO 2026
HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA)source ↗
●Corporate ApprovalCorporate
Board approved new $500 million share repurchase program
▼Label ExpansionZepzelcaApprovedFDA Decision
FDA approved label supplement removing Zepzelca second-line indication
second-line small-cell lung cancer (indication removal)source ↗
▲AcquiredCorporate
Jazz completes acquisition of Actio Biosciences for $820 million upfront
●Partnership / LicenseCorporate
Actio spun out new private entity holding non-ABS-1230 programs; Jazz received minority stake and related rights
▲AcquiredABS-1230Corporate
Closed acquisition of Actio Biosciences, adding ABS-1230 (JZP6979)
KCNT1-related epilepsysource ↗
▲Topline ReadoutZanidatamabApprovedClinical Data
Second interim top-line OS results from HERIZON-GEA-01
HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA)source ↗
Unlock the full JAZZ catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How JAZZ actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-12JZP3507 (formerly ONC206) Pre-clinical data presentation Pre-clinical
Unlock 14 more JAZZ historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
12
Drugs Scored
rNPV / MCap
Top Drug
Top 5%
Mid Cap
(rank 37 of 725)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
ProductRevenuePrior periodChange
Xywav
Epidiolex/Epidyolex
Rylaze/Enrylaze
Zepzelca
Defitelio/defibrotide
Modeyso
Xyrem
Vyxeos
Ziihera
Showing 68 of 113 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Zanidatamab BiologicsMarketedNCT06282575Biliary Tract CancerApproved RECRUITING 286Apr 1, 2030
Zanidatamab BiologicsMarketedNCT05152147Gastric NeoplasmsApproved ACTIVE NOT_RECRUITING 920Sep 30, 2027
Zanidatamab BiologicsNCT06435429Metastatic HER2-positive Breast CancerPhase 3 RECRUITING 550Oct 18, 2030
Zanidatamab BiologicsMarketedNCT06043427Gastroesophageal AdenocarcinomaApproved RECRUITING 168Jul 31, 2027
Zanidatamab BiologicsNCT06695845Breast CancerPhase 2 RECRUITING 200Dec 31, 2027
Zanidatamab BiologicsNCT07102381HER2-positive Breast CancerPhase 2 RECRUITING 125May 2, 2030
CBD-OS Small MoleculesNCT07723976Developmental and Epileptic Encephalopathy (DEE)Phase 3 RECRUITING 120Sep 4, 2029
CBD-OS Small MoleculesNCT07233239Focal SeizuresPhase 1 RECRUITING 100Nov 29, 2027
JZP926 Small MoleculesNCT07723963Juvenile Myoclonic EpilepsyNDA/BLA RECRUITING 260Aug 1, 2028
JZP3507 Small MoleculesNCT07533942MeningiomaPhase 2 RECRUITING 30Oct 16, 2031
ONC206 Small MoleculesNCT07282587Advanced Pheochromocytoma and ParagangliomaPhase 2 RECRUITING 90Dec 15, 2028
ONC206 Small MoleculesNCT04541082Central Nervous System NeoplasmsPhase 1 ACTIVE NOT_RECRUITING 35Sep 30, 2027
JZP898 Small MoleculesNCT06108050Advanced Solid TumorPhase 1 RECRUITING 177May 31, 2028
JZP815 Small MoleculesNCT05557045Advanced CancerPhase 1 ACTIVE NOT_RECRUITING 98Apr 1, 2028
JZP269 Small MoleculesNCT07813663UndisclosedPhase 1 RECRUITING 212Feb 27, 2027
JZP047 Small MoleculesNCT07377539UndisclosedPhase 1 ACTIVE NOT_RECRUITING 86Nov 30, 2026
Lurbinectedin Small MoleculesMarketedNCT05091567Small-Cell Lung CancerApproved ACTIVE NOT_RECRUITING 676Feb 28, 2028
Lurbinectedin Small MoleculesMarketedNCT07459634Extensive-stage Small-cell Lung CancerApproved RECRUITING 50Nov 4, 2029
Lurbinectedin Small MoleculesNCT05734066Refractory Ewing SarcomaPhase 1/2 RECRUITING 60Apr 20, 2028
Lurbinectedin Small MoleculesMarketedNCT05244239Extensive Stage Lung Small Cell CarcinomaApproved RECRUITING 22Jul 28, 2027
Vyxeos Small MoleculesMarketedNCT04217278Acute Myeloid LeukaemiaApproved ACTIVE NOT_RECRUITING 333May 1, 2026
Xywav Small MoleculesMarketedNCT07625280NarcolepsyApproved RECRUITING 120Jan 6, 2028
Dordaviprone Small MoleculesMarketedNCT05580562H3 K27MApproved RECRUITING 510Jun 1, 2028
Vyxeos Small MoleculesMarketedNCT05260528Acute Myeloid LeukemiaApproved RECRUITING 248Feb 2, 2030
CPX-351 Small MoleculesMarketedNCT03897127Acute Myeloid LeukemiaApproved ACTIVE NOT_RECRUITING 1,252Jun 1, 2027
Unlock the JAZZ pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every JAZZ program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Ziihera
BreakthroughPriority
HER2-positive advanced gastroesophageal adenocarcinomaPhase 32026-10-23Median OS reached 27.0 months; 39.8% with Ziihera plus tislelizumab and chemotherapy alive at three years; Median OS was 22.9 months with Ziihera plus chemotherapy; Median OS was 19.6 months with trastuzumab plus chemotherapy; Ziihera plus chemotherapy reduced the risk of death by 24% (HR 0.76); Ziihera plus tislelizumab and chemotherapy reduced the risk of death by 35% (HR 0.65)Read MoreZiihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026Read More
Scroll for more · summaries link to the source press release
Unlock every JAZZ trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock JAZZ insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
COZADD BRUCE CDirectorOption 734 340,609 held$136.18 11/06/2026
Unlock the full JAZZ insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Sofinnova Investments, Inc. 4.2 % (-8.7 %) 97.79 M 422.38 K 15.61% ( 57.03 K)
Unlock every fund holding JAZZ
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in JAZZ
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see JAZZ ownership
Insider and institutional ownership, quarter by quarter.

JAZZ Short Interest

Shares sold short, counted twice a month.

9.4%
Short % of Float
of tradable shares sold short
5.8M
Shares Sold Short
-1.1% vs prior count
7.7 High
Days to Cover
trading days of normal volume to buy every short share back
755.7K
Avg Daily Volume
the average used for days to cover
Unlock JAZZ short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock JAZZ option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live JAZZ option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock JAZZ options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How JAZZ ranks across every disease it competes in

Competitive Position is a premium feature
See how JAZZ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

JAZZ News

JAZZ
Nov 3, 2026
JAZZConferences/Events

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

Jazz Pharmaceuticals announced its participation in several upcoming investor conferences. Management will hold fireside chats at the Jefferies London Global Healthcare Conference on November 17, and at the Piper Sandler and Citi's Global Healthcare Conferences on December 2. Audio webcasts of these events will be available on the company's website.

Read more →
JAZZ
Nov 2, 2026
JAZZGeneral
▲ +7.1%on this newsshared move

Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results

Jazz Pharmaceuticals reported third quarter 2026 revenues of $1.2 billion, a 10% increase year-over-year. The company raised its full-year revenue guidance and successfully launched Ziihera for HER2-positive gastroesophageal adenocarcinoma. Despite a GAAP net loss of $483.4 million, the acquisition of Actio strengthens its rare epilepsy portfolio.

Read more →
JAZZ
Nov 2, 2026
JAZZConferences/Events

Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026

Jazz Pharmaceuticals will present neuro-oncology data at the 2026 Society for Neuro-Oncology Annual Meeting in Philadelphia. The company highlighted the ongoing Phase 3 ACTION trial for Modeyso in diffuse glioma and a new Phase 2 study for JZP3507 in recurrent meningioma. These presentations detail progress on novel therapies targeting rare brain cancers.

Read more →
JAZZ
Oct 23, 2026
JAZZPhases

Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026

Jazz Pharmaceuticals reported updated results from the Phase 3 HERIZON-GEA-01 trial at ESMO 2026. The trial showed that Ziihera combined with tislelizumab and chemotherapy achieved a median overall survival of 27 months, significantly better than trastuzumab. Nearly 40% of patients were alive at three years, indicating a durable survival benefit.

Read more →
JAZZ
Oct 19, 2026
JAZZConferences/Events

Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026

Jazz Pharmaceuticals has announced that it will report its third quarter financial results for 2026 on November 2, 2026. The report will be released after the close of U.S. financial markets, followed by a management-hosted webcast at 4:30 p.m. ET. Interested parties can register for the call in advance through the company's website.

Read more →
JAZZ
Sep 15, 2026
JAZZGeneral

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals has successfully acquired Actio Biosciences for $820 million, enhancing its epilepsy pipeline with the addition of ABS-1230, a potential first-in-class therapy for KCNT1-related epilepsy. ABS-1230 has shown promising results in early trials, indicating significant seizure reductions in children. The acquisition aims to leverage Actio's precision biology expertise alongside Jazz's development capabilities.

Read more →
JAZZ
Aug 31, 2026
JAZZPhases

Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA

Jazz Pharmaceuticals announced positive interim results from the Phase 3 HERIZON-GEA-01 trial, showing that Ziihera (zanidatamab-hrii) combined with chemotherapy significantly improves overall survival compared to trastuzumab plus chemotherapy for HER2+ gastroesophageal adenocarcinoma. The FDA recently approved Ziihera for first-line treatment, reinforcing its role as a new standard of care. The safety profile remains consistent with prior studies.

Read more →
JAZZ
Aug 27, 2026
JAZZGeneral

Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

Jazz Pharmaceuticals has announced the pricing of an upsized $1.1 billion offering of 1.875% exchangeable senior notes due 2032. The offering, which includes an option for additional notes, is expected to close on August 31, 2026. Concurrently, the company plans to repurchase approximately $225 million of its ordinary shares. The proceeds from the notes will be used for general corporate purposes.

Read more →
JAZZ
Aug 26, 2026
JAZZGeneral

Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

Jazz Pharmaceuticals has announced a private offering of $1.0 billion in exchangeable senior notes due 2032, aimed at qualified institutional buyers. The company will also repurchase up to $225 million of its ordinary shares concurrently with the offering. The proceeds from the offering are intended for general corporate purposes, although market conditions may affect the transaction.

Read more →
JAZZ
Aug 25, 2026
JAZZFDA Updates

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Jazz Pharmaceuticals announced FDA approval for Ziihera (zanidatamab-hrii) in combination with tislelizumab and chemotherapy for first-line treatment of advanced HER2-positive gastroesophageal adenocarcinoma. This approval establishes a new standard of care and is based on the HERIZON-GEA-01 trial results, which demonstrated significant improvements in overall and progression-free survival. The approval is significant for patients with limited treatment options.

Read more →
JAZZ
Aug 10, 2026
JAZZGeneral

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Jazz Pharmaceuticals has announced its acquisition of Actio Biosciences for $820 million upfront, with potential additional payments of up to $500 million. This acquisition includes ABS-1230, a novel therapy for KCNT1+ epilepsy, a rare condition with no current FDA-approved treatments. The deal is expected to close in the fourth quarter of 2026, pending customary conditions.

Read more →
JAZZ
Aug 3, 2026
JAZZGeneral

Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

Jazz Pharmaceuticals reported strong financial results for the second quarter of 2026, achieving record revenues of $1.2 billion, a 16% increase year-over-year. The company raised its revenue guidance for the year, anticipating continued growth driven by its key products, including Xywav and Epidiolex. Additionally, Jazz is preparing to launch its new drug Ziihera pending FDA approval.

Read more →
JAZZ
Jul 20, 2026
JAZZConferences/Events

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026

Jazz Pharmaceuticals has announced that it will report its second quarter financial results on August 3, 2026. The report will be released after the U.S. financial markets close, followed by a management-hosted webcast at 4:30 p.m. ET. Interested parties can register in advance for the call and access a replay via the company's website.

Read more →
JAZZ
Jun 17, 2026
JAZZGeneral

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

Jazz Pharmaceuticals and AbCellera have announced a preclinical collaboration to develop T-cell engaging multispecific antibodies targeted at gastrointestinal cancers and other solid tumors. The agreement includes $56 million in upfront payments and up to $792 million in potential milestone payments. Jazz has the exclusive option to develop any therapeutic antibodies that result from the collaboration, further enhancing its oncology portfolio. This partnership is expected to leverage AbCellera's advanced antibody discovery capabilities to provide novel treatment options for difficult-to-treat cancers.

Read more →
JAZZ
Jun 16, 2026
JAZZConferences/Events

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

Jazz Pharmaceuticals presented 11 late-breaking data sets at SLEEP 2026 regarding Xywav for narcolepsy and idiopathic hypersomnia. The company highlighted real-world evidence showing improved patient outcomes and reduced cardiometabolic risk markers. Data indicated that mean time to reach a stable dose was approximately 42 days for both conditions. Additionally, initiation of Xywav was linked to decreases in systolic blood pressure and increases in HDL cholesterol.

Read more →
JAZZ
Jun 12, 2026
JAZZPhases

Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer

Jazz Pharmaceuticals announced that the Phase 3 LAGOON trial for Zepzelca (lurbinectedin) in second-line small cell lung cancer did not meet its primary endpoint of overall survival. Despite this, the safety profile remained consistent with previous data. The company plans to discuss the results with the FDA regarding post-marketing requirements for the second-line indication.

Read more →
JAZZ
Jun 4, 2026
JAZZConferences/Events

Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia

Jazz Pharmaceuticals will present 21 abstracts at SLEEP 2026, including 11 late-breaking presentations. The data focuses on Xywav treatment for narcolepsy and idiopathic hypersomnia. Key findings cover sleep inertia improvements and real-world dosing patterns. These results reflect ongoing clinical research into these rare sleep disorders.

Read more →
JAZZ
May 27, 2026
JAZZPhases

Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

Jazz Pharmaceuticals announced the publication of Phase 3 HERIZON-GEA-01 trial results in the New England Journal of Medicine, which showcase the efficacy and safety of Ziihera (zanidatamab-hrii). The trial demonstrated significant improvements in progression-free survival and overall survival outcomes in patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. Additional analyses revealed consistent benefits across different PD-L1 expression levels, reinforcing zanidatamab's clinical potential. The findings could reshape first-line treatment expectations for this cancer indication.

Read more →

About Jazz Pharmaceuticals plc

Waterloo Exchange, DUBLIN 2,890 employees jazzpharmaceuticals.com
HeadquartersFIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN, D04 E5W7
BIOPHARMAWATCH ELITE
Trade the next JAZZ catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime